Bicnu, Gliadel (carmustine) is a small molecule pharmaceutical. Carmustine was first approved as Bicnu on 1982-01-01. It is used to treat brain neoplasms, carcinoma, colonic neoplasms, ependymoma, and glioblastoma amongst others in the USA. It has been approved in Europe to treat hodgkin disease and non-hodgkin lymphoma. The pharmaceutical is active against glutathione reductase, mitochondrial.
|Trade Name||Bicnu, Gliadel|
|Indication||brain neoplasms, carcinoma, colonic neoplasms, ependymoma, glioblastoma, hodgkin disease, lung neoplasms, medulloblastoma, melanoma, multiple myeloma, non-hodgkin lymphoma|
|Drug Class||Antineoplastics (chloroethylamine derivatives)|